Stock listing

NASDAQ:JSPR Jasper Therapeutics, Inc. Stock

Home listing (NASDAQ) of Jasper Therapeutics, Inc.

Follow Jasper Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:JSPR

$8.69 USD -2.06 (-19.2%)

Close on Nov 20, 2026

Past year +393.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.47 – $12.00 USDNov 20, 2026
Volume
11,716 sharesNov 20, 2026
Market cap
$9.64M USDAt the close on Nov 20, 2026 · price × 1.11M shares outstanding
52-week range
$0.315 – $17.03 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$105,926 USDMedian day 12,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Jasper Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:JSPR · Home$8.69 USD-2.06 (-19.2%)11,716$10.95$12.00$8.47$10.75Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JSPR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.69-2.06-19.2%$10.95$12.00$8.4711,716
$10.75-0.77-6.7%$10.69$11.50$10.6110,900
$11.52+1.18+11.4%$10.67$11.86$10.6619,300
$10.34-1.43-12.1%$11.96$12.00$9.2549,000
$11.77-1.91-14.0%$13.67$14.35$11.7723,500
$13.68+0.31+2.3%$13.51$14.56$12.9316,500
$13.37-1.39-9.4%$14.27$14.99$13.3732,400
$14.76+0.01+0.1%$15.04$15.45$13.6469,500
$14.75-1.62-9.9%$15.24$15.87$14.0947,200
$16.37-0.49-2.9%$17.03$17.03$14.2653,300
$16.86+2.79+19.8%$12.76$17.00$12.7663,400
$14.07-1.26-8.2%$14.91$14.94$13.5017,857
$15.33+0.93+6.5%$13.98$15.60$13.2026,087
$14.40-0.84-5.5%$15.27$15.90$14.108,720
$15.24+14.72+2830.8%$15.57$16.50$14.9415,073
$0.52-0.012-2.3%$0.516$0.554$0.51113,200
$0.532-0.007-1.3%$0.533$0.563$0.51113,770
$0.539+0.02+3.9%$0.50$0.548$0.5012,373
$0.519+0.014+2.8%$0.477$0.53$0.4644,140
$0.505-0.005-1.0%$0.51$0.521$0.49513,223
$0.51+0.014+2.8%$0.496$0.54$0.48410,783
$0.496-0.008-1.6%$0.50$0.515$0.492,410
$0.504+0.004+0.8%$0.52$0.54$0.49711,960
$0.50+0.023+4.8%$0.478$0.529$0.47712,217
$0.477-0.003-0.6%$0.47$0.49$0.4613,050
$0.48-0.052-9.8%$0.546$0.55$0.4788,187
$0.532+0.031+6.2%$0.49$0.545$0.47612,667
$0.501+0.005+1.0%$0.501$0.517$0.4620,670
$0.496-0.059-10.6%$0.54$0.54$0.49614,310
$0.555-0.015-2.6%$0.569$0.577$0.54511,193
$0.57+0.01+1.8%$0.547$0.577$0.5418,730
$0.56-0.01-1.8%$0.563$0.58$0.5412,073
$0.57+0.01+1.8%$0.543$0.59$0.5412,173
$0.56-0.033-5.6%$0.60$0.60$0.5510,930
$0.593+0.028+5.0%$0.57$0.596$0.54212,533
$0.565-0.033-5.5%$0.60$0.615$0.5637,870
$0.598+0.018+3.1%$0.59$0.64$0.5859,820
$0.58-0.045-7.2%$0.62$0.655$0.57217,950
$0.625-0.001-0.2%$0.642$0.675$0.58430,523
$0.626+0.017+2.8%$0.606$0.656$0.608,370
$0.609+0.024+4.1%$0.593$0.62$0.5795,437
$0.585+0.018+3.2%$0.592$0.592$0.54421,140
$0.567-0.056-9.0%$0.628$0.648$0.56714,233
$0.623+0.02+3.3%$0.629$0.651$0.60610,337
$0.603-0.015-2.4%$0.636$0.67$0.606,867
$0.618-0.016-2.5%$0.63$0.65$0.607,427
$0.634+0.053+9.1%$0.59$0.66$0.5910,120
$0.581+0.011+1.9%$0.577$0.609$0.5616,843
$0.57-0.063-10.0%$0.64$0.644$0.56813,420
$0.633-0.027-4.1%$0.66$0.668$0.6013,477
$0.66-0.041-5.8%$0.693$0.711$0.669,810
$0.7010.000.0%$0.69$0.73$0.696,930
$0.701-0.008-1.1%$0.701$0.714$0.682,010
$0.7090.000.0%$0.739$0.74$0.6956,330
$0.709+0.023+3.4%$0.67$0.71$0.66414,427
$0.686-0.019-2.7%$0.693$0.71$0.65312,133
$0.705+0.007+1.0%$0.688$0.72$0.6812,677
$0.698-0.013-1.8%$0.70$0.711$0.63528,473
$0.711+0.011+1.6%$0.715$0.74$0.65512,933
$0.70+0.001+0.1%$0.71$0.71$0.668,913
$0.699-0.019-2.6%$0.707$0.744$0.698,473
$0.718-0.002-0.3%$0.714$0.721$0.6928,203
$0.72-0.002-0.3%$0.709$0.74$0.6999,050
$0.722+0.006+0.8%$0.73$0.735$0.67411,803
$0.716+0.025+3.6%$0.68$0.736$0.67526,027
$0.691-0.056-7.5%$0.735$0.76$0.67877,870

Splits

1 split · NASDAQ:JSPR · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:JSPR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Jasper Therapeutics, Inc. news

Jasper Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 97 in all · newest Nov 16, 2026 · oldest 2021
Decks
22 decks · latest September 2026

Where Jasper Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:JSPR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:JSPRBOATSUnited StatesUSD

Valuation

EV/sales −15.7× against a median of −5.9×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$125.6M USD
P/E
Loss
EV/sales
−15.7×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
2.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Alzinova AB · OMXSTO:ALZUS$9.57MUS$8.34Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
Median of the othersUS$9.57MUS$4.33M0.1×−5.9×0.6×−303.7%0.0×0.88

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
600.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.90 · 2 analysts
Revenue, year to Dec 2026
6M · 2 analysts

Team and board

Officers

OfficerRole
Jeet MahalChief Executive Officer
Rick RuizVice President, Finance
Matthew RosChief Operating Officer
Abby KennedyVice President, Clinical Operations
Helen FuVice President, Corporate Portfolio and Project Management
Lisa PittSenior Vice President, Regulatory Affairs
Mark CamarenaVice President, Information Technology and Facilities
Matt FordSenior Vice President, Human Resources
Shiguang LiuVice President, Clinical Development
Wenru SongExecutive Vice President and Head of R&D
Greg KeenanChief Medical Officer

Board

DirectorRole
Thomas WiggansChairman of the Board
Judith ShizuruBoard Member
Kurt von EmsterBoard Member
Patrick CrutcherBoard Member
Svetlana LucasBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−12.2%
Q2 2026Aug 14, 2026 · Before open−8.5%
Q1 2026May 14, 2026 · After close−11.4%
Q3 2025Nov 10, 2025 · Before open0.0%
Q2 2025Aug 13, 2025 · After close+2.0%
Q1 2025May 12, 2025 · Before open+4.9%
Q4 2024Feb 27, 2025 · Before open−2.2%
Q3 2024Nov 7, 2024 · Before open−4.3%
Q2 2024Aug 13, 2024 · Before open+12.4%
Q1 2024May 14, 2024 · Before open+0.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 4, 2024 · Before open+0.9%
Q3 2023Nov 9, 2023 · Before open−8.1%
Q2 2023Aug 11, 2023 · After close−4.3%
Q1 2023May 12, 2023 · After close−0.6%
Q4 2022Mar 8, 2023 · After close−7.0%
Q3 2022Nov 10, 2022 · After close+1.5%
Q2 2022Aug 12, 2022 · After close−7.1%
Q1 2022May 12, 2022 · After close+2.0%
Q4 2021Mar 18, 2022 · After close+1.1%
Quarter to Sep 30, 2021Nov 12, 2021 · After close+4.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck29 slidesSeptember 2026
Merger or Acquisition (July 2026)Merger or acquisition30 slidesJul 17, 2026
JPM TMT Conference (January 2026)Conference14 slidesJan 8, 2026
Corporate Update (January 2026)Corporate update20 slidesJan 8, 2026
Corporate Update (December 2025)Corporate update31 slidesDec 2, 2025
Investor Presentation (July 2025)Investor deck24 slidesJul 7, 2025
Corporate Update (June 2025)Corporate update19 slidesJun 16, 2025
Technical Presentation (January 2025)Technical27 slidesJan 8, 2025
Technical Presentation (June 2024)Technical13 slidesJun 2, 2024
EAACI Congress 2024Conference20 slidesJun 1, 2024
All 22 decks
DeckKindSlidesDate
Technical Presentation (March 2024)Technical12 slidesMarch 2024
ASH Annual Meeting 2023Conference16 slidesDec 10, 2023
Investor Presentation (October 2023)Investor deck29 slidesOct 10, 2023
Investor Presentation (June 2023)Investor deck55 slidesJun 2, 2023
Investor Presentation (January 2023)Investor deck51 slidesJan 24, 2023
Investor Presentation (January 2023)Investor deck37 slidesJan 10, 2023
Technical Presentation (April 2022)Technical18 slidesApr 27, 2022
Investor Presentation (March 2022)Investor deck8 slidesMar 16, 2022
Amplitude Healthcare Acquisition — SPAC Merger (September 2021)SPAC merger33 slidesSep 9, 2021
Amplitude Healthcare Acquisition — SPAC Merger (June 2021)SPAC merger36 slidesJun 8, 2021
SPAC Merger (May 2021)SPAC merger20 slidesMay 7, 2021
SPAC Merger (May 2021)SPAC merger77 slidesMay 6, 2021

Open Decks

Financings

RaiseDate
Private placement of non-voting convertible preferred stock
Closed: US$132M raised · Piper Sandler & Co. +1
Dealers: Piper Sandler & Co. (lead), LifeSci Capital LLC (co-lead)
Buyers: Affinity Asset Advisors, LLC (co-led the private placement); Ikarian Capital LLC (co-led the private placement); Columbia Threadneedle Investments; Sirenia Capital Management LP; Brahma Capital; Balyasny Asset Management; SilverArc Capital; Squadron Capital Management; Nazare Partners LP; Mirador Therapeutics
Use of proceeds: Fund development of the combined company's pipeline through the second half of 2028
Aug 17, 2026
Public offering of common stock and warrants
Closed: US$30M raised · US$2.43 a share · Warrants at US$2.92 for 48 months · TD Cowen
Dealers: TD Cowen (lead)
Use of proceeds: Extends cash runway through the first half of 2026
Nov 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Amplitude Healthcare Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a unit on Nov 19, 2019.

Price
US$10.00 a unit
Units offered
10,000,000 units
Offering size
US$100 million
Underwriters' option
Up to 1,500,000 more units
Listing
AMHCU on the Nasdaq Capital Market
Underwriters
BMO Capital Markets, SVB Leerink · In the order on the cover
Units delivered
On or about Nov 22, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceSep 13, 2019
Filed publiclyOct 25, 2019
Amended 3 timesNewest Nov 14, 2019
Shares registered with an exchangeNov 18, 2019
Declared effective by the SECNov 19, 2019
Final prospectus, with the priceNov 21, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue00013.5M6.20M0
Cost of revenue41.6M34.3M1.11M1.31M566.0K21.0K
Gross profit-1.06M-1.37M-1.11M-1.31M-566.0K-21.0K
Research and development63.1M55.8M51.8M34.6M25.4M15.9M3.62M
Selling, general and administrative18.9M20.4M17.1M16.6M11.4M4.80M1.09M
Operating income-83.9M-76.2M-68.9M-51.2M-36.8M-20.7M-4.71M
Depreciation and amortization1.06M1.37M1.11M975.0K377.0K21.0K4.71M
EBITDA-82.8M-74.9M-67.8M-50.2M-36.5M-20.7M0
Interest expense13.5M6.20M11.0M0
Income before tax-75.8M-71.3M-64.5M-37.7M-30.6M-6.44M-4.99M
Income tax2.00K2.00K-13.5M-1.09M38.5K-277
Net income-75.8M-71.3M-64.5M-37.7M-30.6M-31.7M-4.99M
Earnings per share, basic-3.95-4.89-6.18-10.33-2.69-5.17-28.34
Earnings per share, diluted-3.95-4.89-6.18-10.33-2.69-5.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents28.7M71.6M86.9M38.3M84.7M19.8M27.2M
Short-term investments100.2M
Receivables250.0K1.16M698.0K600.0K
Inventory-548.0K95.5K
Current assets34.6M75.8M88.9M41.7M87.8M20.7M27.2M
Property, plant and equipment102.0K1.88M2.73M3.57M3.69M693.0K
Total assets35.8M79.9M94.9M48.4M93.7M23.4M27.2M
Accounts payable6.22M4.03M4.15M1.77M3.92M1.42M623.0K
Current liabilities13.2M15.2M12.4M7.07M8.02M4.01M1.99M
Long-term debt13.1M
Total debt1.24M1.81M2.79M3.65M2.88M1.62M
Total liabilities31.6M18.2M16.5M12.4M24.1M14.6M6.11M
Shareholders' equity4.15M61.7M78.4M36.0M69.5M-35.1M21.1M
Shares outstanding933.2K15.0M11.2M3.80M37.9M2.77M176.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-77.2M-62.6M-52.1M-45.9M-33.7M-18.3M-1.97M
Capital spending-7.00K-552.0K-267.0K-576.0K-2.43M-2.43M-2.43M
Free cash flow-77.2M-63.2M-52.3M-46.4M-36.1M-18.3M-1.97M
Cash from investing5.00K-532.0K-267.0K-576.0K-2.43M198.3K-2.43M
Cash from financing34.2M47.9M101.0M55.0K101.0M11.3M29.1M
Share buybacks243.0K360.0K-960.0K28.0K5.70M
Change in cash-42.9M-15.3M48.6M-46.4M64.9M-442.6K27.2M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
8-K · Current reportNov 13, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportNov 4, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2026Big-stake noticeSEC
SC TO-I/AOct 23, 2026Acquisition or disposalSEC
DEF 14A · Proxy statementOct 20, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 15, 2026Current reportSEC
S-3 · Registration statementOct 14, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementOct 9, 2026Meeting noticeSEC
8-K · Current reportOct 7, 2026Current reportSEC
SC TO-IOct 7, 2026Acquisition or disposalSEC
8-K · Current reportOct 5, 2026Meeting outcomeSEC
8-K/A · Current report, amendedOct 2, 2026Current reportSEC
8-K/A · Current report, amendedOct 1, 2026Current reportSEC
8-K · Current reportSep 28, 2026Management or board changeSEC
25-NSESep 24, 2026Other filingsSEC
DEF 14A · Proxy statementSep 4, 2026Meeting noticeSEC
8-K · Current reportAug 26, 2026Material contractSEC
PRE 14A · Preliminary proxy statementAug 24, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeAug 17, 2026Big-stake noticeSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
DAug 4, 2026Other filingsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Meeting outcomeSEC
8-K · Current reportJul 31, 2026Current reportSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 22, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 22, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 20, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 20, 2026Big-stake noticeSEC
8-K · Current reportJul 16, 2026Acquisition or disposalSEC
8-K · Current reportJul 16, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 10, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersJun 15, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 15, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 15, 2026Meeting noticeSEC
8-K · Current reportJun 9, 2026Current reportSEC
8-K · Current reportJun 1, 2026Current reportSEC
8-K · Current reportMay 21, 2026Management or board changeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 25, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 26, 2026Big-stake noticeSEC
8-K · Current reportJan 8, 2026Current reportSEC
8-K · Current reportJan 7, 2026Management or board changeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 2, 2025Big-stake noticeSEC
8-K · Current reportDec 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 23, 2025Big-stake noticeSEC
8-K · Current reportSep 19, 2025Material contractSEC
424B5 · ProspectusSep 19, 2025Offer documentSEC
424B5 · ProspectusSep 18, 2025Offer documentSEC
8-K · Current reportAug 13, 2025ResultsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 11, 2025Big-stake noticeSEC
8-K · Current reportJul 9, 2025Management or board changeSEC
8-K · Current reportJul 7, 2025Current reportSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
8-K · Current reportJul 3, 2025Meeting outcomeSEC
8-K · Current reportJun 16, 2025Current reportSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
ARS · Annual report to shareholdersMay 19, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 19, 2025Meeting noticeSEC
8-K · Current reportMay 12, 2025ResultsSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMar 27, 2025Other filingsSEC
424B5 · ProspectusMar 26, 2025Offer documentSEC
CORRESP · Letter to the SECMar 24, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 21, 2025Other filingsSEC
8-K · Current reportMar 19, 2025Material contractSEC
S-3 · Registration statementMar 19, 2025Offer documentSEC
10-K · Annual reportFeb 28, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
8-K · Current reportJan 8, 2025Current reportSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
144 · Notice of proposed saleDec 12, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
8-K · Current reportOct 15, 2024Current reportSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Management or board changeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
144 · Notice of proposed saleJun 12, 2024Other filingsSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
8-K · Current reportJun 12, 2024Management or board changeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
S-8 POSJun 7, 2024Offer documentSEC
S-8 POSJun 7, 2024Offer documentSEC
S-8 POSJun 7, 2024Offer documentSEC
S-8 · Registration statement for employee plansJun 7, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialMay 3, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 22, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2024Meeting noticeSEC
SC 13G · Big-stake noticeMar 27, 2024Big-stake noticeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
144 · Notice of proposed saleMar 12, 2024Other filingsSEC
144 · Notice of proposed saleMar 6, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 5, 2024Offer documentSEC
10-K · Annual reportMar 5, 2024Annual reportSEC
8-K · Current reportMar 4, 2024ResultsSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
424B5 · ProspectusFeb 6, 2024Offer documentSEC
8-K · Current reportFeb 6, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 2, 2024Big-stake noticeSEC
8-K · Current reportJan 4, 2024Current reportSEC
8-K · Current reportJan 2, 2024Current reportSEC
8-K · Current reportDec 20, 2023Meeting outcomeSEC
4 · Change in ownershipNov 30, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 20, 2023Insider tradeSEC
DEF 14A · Proxy statementNov 20, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 9, 2023Meeting noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
4 · Change in ownershipNov 2, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2023Insider tradeSEC
8-K · Current reportNov 1, 2023Management or board changeSEC
8-K · Current reportOct 20, 2023Current reportSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC

This page holds 200 of 489 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Jasper Therapeutics, Inc.’s releases · as of Nov 6, 2026

Common shares
1,109,152
Fully diluted
13,582,665

Fully diluted

LineSharesAs of
Common shares1,109,152Nov 6, 2026
Warrants12,473,513Sep 22, 2025

Warrants and options

Lot
Warrants · US$2.92 · expire about Sep 2029

Share count over time

CountShares
Nov 6, 20261,109,152
Nov 6, 2026
Nov 4, 2026

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Bank of America2.11MUS$1.22MSep 30, 2026
Affinity Asset Advisors, LLC1.85MUS$1.07MSep 30, 2026
Acorn Capital Advisors, LLC1.44MUS$834KSep 30, 2026
Kingdon Capital Management, L.L.C.1.35MUS$784KSep 30, 2026
Ikarian Capital, LLC1.34MUS$779KSep 30, 2026
Vanguard1.32MUS$767KSep 30, 2026
Rock Springs Capital Management LP1.1MUS$638KSep 30, 2026
Carlyle Group Inc.1.07MUS$618KSep 30, 2026
Lion Point Capital, LP465KUS$270KSep 30, 2026
Verition Fund Management LLC405KUS$235KSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital300KUS$174KSep 30, 2026
Opaleye Management Inc.281KUS$4.89MSep 30, 2026
Renaissance Technologies253KUS$147KSep 30, 2026
Landscape Capital Management, L.L.C.237KUS$137KSep 30, 2026
Boothbay Fund Management, LLC221KUS$128KSep 30, 2026
Gsa Capital Partners LLP181KUS$105KSep 30, 2026
BlackRock170KUS$98,384Sep 30, 2026
Jane Street167KUS$97,035Sep 30, 2026
JPMorgan148KUS$92,528Sep 30, 2026
Citadel137KUS$79,675Sep 30, 2026
Gts Securities LLC133KUS$76,947Sep 30, 2026
UBS119KUS$68,854Sep 30, 2026
Millennium115KUS$66,585Sep 30, 2026
Seven Grand Managers, LLC70,541US$2MSep 30, 2026
Barclays61,528US$35,686Sep 30, 2026
Osaic Holdings, Inc.45,850US$26,593Sep 30, 2026
State Street44,699US$25,925Sep 30, 2026
Northern Trust41,882US$24,292Sep 30, 2026
Simplex Trading, LLC36,721US$21,298Sep 30, 2026
Diadema Partners LP35,271US$874KSep 30, 2026
Diker Management LLC35,000US$20,300Sep 30, 2026
Susquehanna34,388US$19,945Sep 30, 2026
Two Sigma29,218US$16,946Sep 30, 2026
Virtu Financial LLC28,844US$17,000Sep 30, 2026
DekaBank Deutsche Girozentrale25,000US$16,000Sep 30, 2026
Group One Trading LLC19,930US$11,559Sep 30, 2026
Sequent Planning LLC19,900US$11,542Sep 30, 2026
Rehmann Capital Advisory Group15,300US$8,874Sep 30, 2026
Ieq Capital, LLC13,538US$7,852Sep 30, 2026
R Squared Ltd10,037US$5,821Sep 30, 2026
Tower Research Capital LLC (TRC)7,812US$4,531Sep 30, 2026
Vivo Capital, LLC5,364US$3,693Sep 30, 2026
Morgan Stanley2,997US$1,738Sep 30, 2026
Pinnacle Financial Group, Inc.1,250US$725Sep 30, 2026
Arax Advisory Partners573US$332Sep 30, 2026
National Bank Of Canada160US$93Sep 30, 2026
BNP Paribas141US$82Sep 30, 2026
Jones Financial Companies Lllp50US$30Sep 30, 2026
RBC48Sep 30, 2026
SBI Securities Co., Ltd.14US$8Sep 30, 2026

This page holds 50 of 52 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund833KUS$351KJun 30, 2026
Vanguard Extended Market Index Fund312KUS$131KJun 30, 2026
Fidelity Extended Market Index Fund153KUS$127KMay 31, 2026
Fidelity Total Market Index Fund49,896US$41,364May 31, 2026
Fidelity Series Total Market Index Fund34,109US$28,276May 31, 2026
Vanguard Balanced Index Fund26,598US$11,198Jun 30, 2026
Fidelity Nasdaq Composite Index Fund9,659US$8,007May 31, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND155US$98Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Velan Capital Investment Management LP9.90%3.36MAug 17, 2026Schedule 13G
T. Rowe Price Investment Management, Inc.7.10%2.06MSep 30, 2025Schedule 13G
Bank of America Corp6.40%2.13MSep 30, 2026Schedule 13G
Affinity Asset Advisors, LLC5.60%1.85MSep 30, 2026Schedule 13G
Anders Hove5.30%1.49MJan 23, 2026Schedule 13G
Carlyle Group Inc.3.80%1.09MFeb 18, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Thomas Wiggans
Other companies: Pacira BioSciences, Inc. (Director · Since at least Jun 9, 2026); Annexon, Inc. (Director · Since at least Jul 23, 2020); Pardes Biosciences Inc (Chief Executive Officer, Director · Mar 1, 2022 – Aug 31, 2023 · Past); Forma Therapeutics Holdings Inc (Director · Sep 7, 2020 – Oct 14, 2022 · Past); Somaxon Pharmaceuticals Inc (Director · Jun 11, 2008 – Jul 2, 2012 · Past); Sangamo Therapeutics, Inc. (Director · Jun 4, 2008 – Jun 1, 2011 · Past); Onyx Pharmaceuticals Inc (Director · Aug 29, 2007 – Oct 1, 2013 · Past)
Chairman of the Board · Since at least Nov 1, 2023
William Lis
Other companies: Zai Lab Ltd. (Board Member · Since at least Jan 1, 2021); Eidos Therapeutics Inc (Director · Dec 4, 2018 – Jan 26, 2021 · Past); Portola Pharmaceuticals Inc (Chief Executive Officer, Director · May 21, 2013 – Jul 28, 2018 · Past)
Director · Sep 24, 2021 – Oct 13, 2023 · Past
Kurt von Emster
Other companies: Vera Therapeutics, Inc. (Director · May 13, 2021 – May 17, 2021 · Past); Vaxcyte, Inc. (Director · Jun 11, 2020 – Jun 2, 2021 · Past)
Board Member · Since at least Sep 24, 2021
Greg Keenan
Other companies: Aurinia Pharmaceuticals Inc (SVP, Chief Medical Officer · Since at least Nov 7, 2024)
Chief Medical Officer · Since at least Jul 16, 2026
Abby KennedyVice President, Clinical Operations · Since at least Nov 4, 2026
Greg KeenanChief Medical Officer · Since at least Oct 15, 2026
Helen FuVice President, Corporate Portfolio and Project Management · Since at least Nov 5, 2026
Jeet MahalChief Executive Officer · Since at least Sep 15, 2026
Judith ShizuruDirector · Since at least Sep 24, 2021
Kenneth F CliffordChief Financial Officer · Nov 19, 2019 – Jan 3, 2020 · Past
All 22 people
PersonSeat
Kevin N HellerSee Remarks · Sep 24, 2021 – Mar 21, 2022 · Past
Lisa PittSenior Vice President, Regulatory Affairs · Since at least Sep 15, 2026
Mark CamarenaVice President, Information Technology and Facilities · Since at least Nov 5, 2026
Matt FordSenior Vice President, Human Resources · Since at least Nov 4, 2026
Matthew RosChief Operating Officer · Since at least Jul 16, 2026
Patrick CrutcherBoard Member · Since at least Jul 16, 2026
Rick RuizVice President, Finance · Since at least Nov 4, 2026
Ron MartellPresident, CEO and Director, Director · Since at least Oct 12, 2023
Shiguang LiuVice President, Clinical Development · Since at least Sep 15, 2026
Svetlana LucasBoard Member · Since at least Jul 16, 2026
Vishal KapoorDirector · Since at least Jan 6, 2020
Wenru SongExecutive Vice President and Head of R&D · Since at least Jul 16, 2026

Open People

Log in to ask 6ix AI your own questions about Jasper Therapeutics, Inc.